
Supplements and Featured Publications
- Diving Into Therapeutic Evolutions and Treatment Regimen Nuances for Metastatic Colorectal Cancer
- Volume 01
- Issue 01
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
Martin E. Gutierrez, MD, discusses the mechanism of action of SAR445877 and the role of clinical trials in microsatellite stable colorectal cancer.
“The approved agents don’t work in MSS CRC, but not all immunotherapies are the same.”
Martin E. Gutierrez, MD, director of the Drug Discovery/Phase I Program and co-chief of Thoracic Oncology at John Theurer Cancer Center at Hackensack University Medical Center, as well as a professor in the Department of Oncology at Hackensack Meridian School of Medicine, discussed the mechanism of action of the investigational anti–PD-1/interleukin-15 fusion protein SAR445877 in microsatellite-stable (MSS) colorectal cancer (CRC). He also highlighted why patients with MSS CRC should be considered for clinical trials.
CRC is an immunologically cold tumor, and MSS disease has been a challenge to manage, with patients who have liver disease tending to have the worst outcomes, Gutierrez said. Despite some therapeutic breakthroughs in CRC, most patients run out of treatment options after the classic first, second, and third lines of chemotherapy, he noted.
SAR445877 has an interesting mechanism of action, according to Gutierrez. It is a checkpoint inhibitor directed against PD-1, which blocks the inhibitory modulation of PD-1 on T cells, and it also carries an engineered interleukin-15, which stimulates T cells, particularly CD8-positive T cells, as well as natural killer cells, he explained. The strategy with this agent is to both inhibit the PD-1 mechanisms and reactivate T cells and natural killer cells in the tumor microenvironment, with the goal of converting an immunologically cold tumor into a hot tumor and inducing immunologic responses that tend to be long lasting when successful, Gutierrez said. A phase 1/2 study (NCT05584670) is ongoing to investigate this agent in patients with advanced solid tumors, including MSS CRC, he added.
Gutierrez emphasized that looking for clinical trials is an important first step when planning treatment for patients with MSS CRC. Although approved immunotherapies do not work in MSS CRC, not all immunotherapies are the same, and now is a good time to consider new immunotherapy agents in development, he said. Seeking out these types of studies is important, as their results may change the outlook for diseases that are currently considered unresponsive to immunotherapy, Gutierrez concluded.
Articles in this issue
Related to this article








